Clinical trial · Interventional
TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
Multi-center, Open Label, Phase Ib Clinical Trial to Evaluate Safety, Tolerance and Efficacy of TASO(TGF-β2 Targeting Anti-sense Oligonucleotide)-001 in Combination With Recombinant Interleukin-2 in Advanced or Metastatic Solid Tumor
NCT04862767CI-TRIAL-00073458completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate safety, tolerance and efficacy of TASO(TGF-β2 targeting anti-sense oligonucleotide)-001 in combination with recombinant interleukin-2(Aldesleukin) in advanced or metastatic solid tumor and to find appropriate dose for phase 2 clinical trial.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aldesleukin | Combination Product | — | UNRESOLVED |
| TASO-001((TGF-β2 targeting anti-sense oligonucleotide) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TASO-001
- description
- level 1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)(3+3) next than level 2 or level -1 of TASO-001 in combination with recombinant IL-2(Aldesleukin)
- interventionNames
- Drug: TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
- Combination Product: Aldesleukin
Primary outcomes (1)
- measure
- Incidence of MTD (Tolerability)
- timeFrame
- 4weeks(DLT)
- description
- MTD and RP2D are determined
Secondary outcomes (5)
- measure
- ORR(objective response rate)
- timeFrame
- every 8 weeks, and up to 14 days after the last dose of TASO-001
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults over 19 years old on the day of consent 2. Pathologically confirmed solid cancer 3. Patients with advanced or metastatic solid timour failed or tolerable with standard therapy. 4. A person who has a tumor lesion that can safely undergo tissue biopsy during administration of the test drug and can provide tissues stored at the clinical trial agency or tissue obtained from a tissue biopsy conducted before the first administration of the test drug Exclusion Criteria: 1. Those who have been treated with IL-2 or TGF-β inhibitors other than test drugs (e.g., anti-sense oligonucleotide, antibody, TGF-b receptor inhibitor) 2. Chemotherapy within 21 days or at least 5 half-lives (whichever is shorter) prior to first dose of study treatment. 3. Immunotherapy within 2 weeks prior to first dose of study treatment. 4. Major surgery within 4 weeks prior to first dose of study treatment.
References
Publications (0)
Data not yet available
No reference posted for this study.